Mynaric AG: Resignation of Bulent Altan as Chairman and Member of Supervisory Board
MUNICH, DE / ACCESS Newswire / March 28, 2025 / Mynaric AG (FRA:M0YN)(OTC PINK:MYNAY) (the 'Company') announces that Bulent Altan today has tendered his resignation as Chairman and Member of the Supervisory Board of the Company for personal reasons effective April 1, 2025.
Bulent Altan was elected Chairman of the Supervisory Board of the Company following his election as member of the Supervisory Board by the General Assembly in August 2023.
The Supervisory Board of the Company will conduct a new election for the role of Chairman without undue delay. A new member will be appointed in due course in accordance with the provisions of applicable stock corporation act (Aktiengesetz).
About Mynaric
Mynaric (FRA:M0YN)(OTC PINK:MYNAY) is leading the industrial revolution of laser communications by producing optical communications terminals for air, space and mobile applications. Laser communication networks provide connectivity from the sky, allowing for ultra-high data rates and secure, long-distance data transmission between moving objects for wireless terrestrial, mobility, airborne- and space-based applications. The company is headquartered in Munich, Germany, with additional locations in Los Angeles, California, and Washington, D.C. For more information, visit mynaric.com.
Forward-Looking Statement
This release includes forward-looking statements. All statements other than statements of historical or current facts contained in this release, including statements regarding our future results of operations and financial position, industry dynamics, business strategy and plans and our objectives for future operations, are forward-looking statements. These statements represent our opinions, expectations, assumptions, beliefs, intentions, estimates or strategies regarding the future, which may not be realized. Forward looking statements are often indicated by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'look forward to,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target' 'will,' 'would' and/or the negative of these terms or other similar expressions that are intended to identify forward-looking statements.
The forward-looking statements included in this release are based largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements involve known and unknown risks, uncertainties and assumptions that are difficult to predict or are beyond our control, and actual results may differ materially from those expected or implied as forward-looking statements. These risks, uncertainties and assumptions include, but are not limited to (i) the impact of any geopolitical tensions or the global COVID-19 pandemic on the global economy, our industry and markets as well as our business, (ii) risks related to our limited operating history, our history of significant losses and the execution of our business strategy, (iii) risks related to our ability to successfully manufacture and deploy our products and risks related to serial production of our products, (iv) risks related to our sales cycle which can be long and complicated, (v) risks related to our limited experience with order processing, our dependency on third-party suppliers and external procurement risks, (vi) risks related to defects or performance problems in our products, (vii) effects of competition and the development of the market for laser communication technology in general, (viii) risks related to our ability to manage future growth effectively and to obtain sufficient financing for the operations and ongoing growth of our business, (ix) risks relating to the uncertainty of the projected financial information, (x) risks related to our ability to adequately protect our intellectual property and proprietary rights and (xi) changes in regulatory requirements, governmental incentives and market developments. Moreover, new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements.
The forward-looking statements included in this release are made only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Unless required under applicable law, neither we nor any other person undertakes any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release or otherwise. You should read this release with the understanding that our actual future results, levels of activity, performance and events and circumstances may materially differ from what we expect.
This release may include certain financial measures not presented in accordance with IFRS. Such financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative to loss for the period or other measures of profitability, liquidity or performance under IFRS. You should be aware that our presentation of these measures may not be comparable to similarly titled measures used by other companies, which may be defined and calculated differently.
Mynaric AG
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
26 minutes ago
- Miami Herald
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
Miami Herald
27 minutes ago
- Miami Herald
Divorced and Facing IRS Collection? Clear Start Tax Outlines How Innocent Spouse Relief Could Save You Thousands
Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse's Mistakes IRVINE, CA / ACCESS Newswire / June 6, 2025 / Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they're on the hook for a former spouse's tax liabilities - often for mistakes they didn't know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS's Innocent Spouse Relief program can offer a powerful - and often overlooked - solution. When Divorce Leaves Taxpayers Facing a Former Spouse's Mistakes Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating. "We've worked with clients blindsided by IRS letters years after their divorce," said the Head of Client Solutions at Clear Start Tax. "Innocent Spouse Relief can be a lifeline in these cases - but most people don't even realize it exists." Who Qualifies for Innocent Spouse Relief? Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims: The tax understatement was due to the other spouse's error (such as unreported income or inflated deductions).The innocent spouse didn't know, and had no reason to know, about the issue at the the innocent spouse liable would be unfair or create innocent spouse applies within the IRS's filing window (generally two years from first collection notice). Why the Right Approach Is Essential for Approval While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt. "Innocent Spouse Relief isn't just a form-it's a carefully built case," said the Head of Client Solutions at Clear Start Tax. "We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner's tax mistakes." How Clear Start Tax Helps Divorced Taxpayers Regain Control Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs: Comprehensive case reviews to assess eligibility and strengthen claimsDetailed preparation of IRS applications with supporting evidenceDirect IRS communication and negotiation on the client's behalfPost-resolution guidance to maintain compliance and peace of mind About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: Contact Information Clear Start TaxCorporate Communications Departmentseo@ 535-1627 SOURCE: Clear Start Tax
Business Journals
43 minutes ago
- Business Journals
In a time of uncertainty, PNW women leaders are charting a course ahead
'Are you a make-it-happen person? Be a make-it-happen person.' This quote from local CEO Molly Moon Neitzel, founder and CEO of Molly Moon's Homemade Ice Cream, embodies the spirit of the day at the third annual Puget Sound Business Journal Women Who Lead Summit, where hundreds of leaders gathered to share their skills and experiences. As we face a time of collective uncertainty, I'm struck by the commitment of our leadership community to lifting one another to drive change. As Schwabe's first female CEO, I've had the privilege of leading for over eight years alongside a board of directors comprising 60% women lawyers. At Schwabe, women in leadership are not the exception — they are the standard. However, many of us at the summit share the experience of being a first in a leadership role or the only woman in the room. The common thread of bringing your whole self into leadership is key to helping all of us grow both personally and professionally and paving the way for others. We are fortunate to have many outstanding examples of authentic and bold leadership right here in Washington, leading global organizations, local businesses, health care organizations, nonprofits, public sector agencies and more. Of the many powerful conversations we've had at the summit, here are three takeaways for all of us who seek to lead with greater intention and purpose. Values-driven leadership can guide you through chaos — and lead to stronger outcomes. Lean into your values and use them as your north star when facing tough conversations or decisions. Keynote speaker Alice Shobe, Amazon's global director of community impact, shared a valuable takeaway with all of us to 'be here, not there.' As leaders, we often feel pulled in a million directions, but one of the most powerful things we can do is focus on being fully present. Stay connected to people who challenge and inspire you. As we recognize the five-year anniversary of the start of the COVID-19 pandemic, I don't take for granted the energy and inspiration that comes from gathering and building community. Finding meaningful ways to connect with entrepreneurs, executives and emerging leaders broadens our perspective and enhances our ability to navigate emerging challenges. Thank you to all the speakers and attendees for making this a memorable celebration of PNW leadership. Let's hold onto the inspiration from this year's summit — and keep showing up, lifting others and making it happen. Schwabe is committed to advancing women in business and law by giving back to our region, providing excellent legal services to our clients, and representing our communities. Our understanding of seven key industry sectors allows us to help clients achieve success through ideas, advice, and exceptional legal counsel: consumer products; manufacturing and retail; health care and life sciences; Indian country and Alaska native corporations; natural resources; ports and maritime; real estate and construction; and technology. Graciela Gomez Cower serves as chief executive officer at Schwabe.
